Neurocrine Biosciences announced that two-year data from their Phase 3 CAHtalyst Adult study shows CRENESSITY (crinecerfont) improves cardiometabolic outcomes like insulin resistance, body weight, and bone health in adults with classic congenital adrenal hyperplasia (CAH). The treatment also sustained reductions in glucocorticoid doses, which are linked to adverse effects. About 37% of overweight participants lost more than 5% of their body weight, and 43% of those with insulin resistance at baseline no longer had it after two years. Patient surveys reported better quality of life and treatment satisfaction. These results highlight CRENESSITY's potential to improve long-term disease management and patient health in CAH.
VYKAT XR (diazoxide choline) treatment demonstrated significant and lasting improvements in hyperphagia and behavioral symptoms in individuals with Prader-Willi syndrome (PWS) for up to three years. Participants who resumed VYKAT XR after a 16-week w...
Neurocrine Biosciences reported that CRENESSITY (crinecerfont) significantly improved hormone levels and reduced glucocorticoid doses in patients with classic congenital adrenal hyperplasia (CAH) due to 11β-hydroxylase deficiency, a rare form of CAH....
Neurocrine Biosciences announced two-year Phase 3 data from the CAHtalyst Pediatric study showing that CRENESSITY (crinecerfont) treatment slows bone age progression and improves predicted adult height in children with classic congenital adrenal hype...
